Sort by

Send to

Choose Destination

Links from PubMed

Items: 19


Towards an understanding of the adjuvant action of aluminium.

Marrack P, McKee AS, Munks MW.

Nat Rev Immunol. 2009 Apr;9(4):287-93. doi: 10.1038/nri2510.


HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team..

Lancet. 2008 Nov 29;372(9653):1894-905. doi: 10.1016/S0140-6736(08)61592-5.


Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team..

Lancet. 2008 Nov 29;372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3.


Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.

Gorse GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, Livingston BD, Villafana TL, Li H, Noonan E, Russell ND; HIV Vaccine Trials Network..

Vaccine. 2008 Jan 10;26(2):215-23.


Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.

Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA.

Nat Med. 2007 Jul;13(7):843-50.


Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.

Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, Chiu YL, McElrath MJ, De Rosa SC.

J Immunol Methods. 2007 May 31;323(1):39-54.


Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.

Bull M, Lee D, Stucky J, Chiu YL, Rubin A, Horton H, McElrath MJ.

J Immunol Methods. 2007 Apr 30;322(1-2):57-69.


Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.

Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D, Koup RA, Roederer M.

J Immunol Methods. 2006 Jun 30;313(1-2):199-208.


Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW.

J Infect Dis. 2005 Mar 1;191(5):666-77.


Vaccination in humans generates broad T cell cytokine responses.

De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, Evans TG, Koup R, Miller CJ, Roederer M.

J Immunol. 2004 Nov 1;173(9):5372-80.


Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2.

Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP, Kwok WW, Migueles SA, Laborico AC, Shupert WL, Hallahan CW, Davey RT Jr, Dybul M, Vogel S, Metcalf J, Connors M.

J Virol. 2003 Oct;77(20):10900-9.


Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection.

Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A.

J Immunol. 2002 Dec 1;169(11):6376-85.


Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.

Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, Appella E, Chesnut R, Sette A, Livingston BD.

J Virol. 2001 May;75(9):4195-207.


Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.

Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Paoletti E, et al.

J Infect Dis. 1998 May;177(5):1230-46.


A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

Valentine FT, Kundu S, Haslett PA, Katzenstein D, Beckett L, Spino C, Borucki M, Vasquez M, Smith G, Korvick J, Kagan J, Merigan TC.

J Infect Dis. 1996 Jun;173(6):1336-46.


The role of lymphoid organs in the immunopathogenesis of HIV infection.

Pantaleo G, Graziosi C, Fauci AS.

AIDS. 1993;7 Suppl 1:S19-23. Review. No abstract available.


A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.

Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A, et al.

N Engl J Med. 1991 Jun 13;324(24):1677-84.

Items per page

Supplemental Content

Support Center